Literature DB >> 8674009

The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology.

D Plantaz1, H Rubie, J Michon, F Mechinaud, C Coze, P Chastagner, D Frappaz, M Gigaud, J G Passagia, O Hartmann.   

Abstract

BACKGROUND: Neuroblastoma is the most common malignant cause of spinal compression in the pediatric population. More than 30% of patients who are impaired prior to treatment remain impaired after the completion of therapy. Those who do not improve after decompressive laminectomy may go on to develop severe delayed spinal deformities.
METHODS: To decrease the long term sequelae of routine neurosurgical intervention for all intraspinal extensions of neuroblastoma, the French NBL 90 Study was formulated to use chemotherapy as a first-line treatment for all nonmetastatic neuroblastomas with intraspinal extension. Neurosurgical decompression and excision was recommended only for patients demonstrating rapid neurologic deterioration.
RESULTS: The overall survival of the 42 patients registered was 97%. Initial neurologic impairment was present in 27 patients (64%), including 11 with paraplegia. Thirty-two patients received chemotherapy as first-line treatment. Complete regression of the intraspinal component was observed in 13 patients and partial regression of greater than 50% of the initial volume in 5 patients. Of 19 evaluable patients presenting with a neurologic deficit and treated with primary chemotherapy, recovery was completed in 11 and partial in 3. Four patients failed to recover from long-standing pretreatment paraplegia. Only one patient worsened during therapy, and recovered completely after emergent neurosurgical intervention. Seven patients underwent initial neurosurgical procedures; six had a neurologic deficit and five recovered completely, including all three who presented with acute onset of paraplegia. Three patients had extraspinal surgery as exclusive treatment. Six patients (15%) suffered severe neurologic sequelae. Only one of the patients who underwent surgery required spinal stabilization for progressive deformity, but follow-up is limited.
CONCLUSIONS: By treating patients with dumbbell neuroblastoma initially with chemotherapy, the authors were able to reduce the size of the intraspinal mass in 58% of patients, improve partial neurologic deficits in 92%, and avoid neurosurgical decompression in 60%. Neurologic deficits also improved in 83% of patients requiring emergent neurosurgical intervention.

Entities:  

Mesh:

Year:  1996        PMID: 8674009     DOI: 10.1002/(SICI)1097-0142(19960715)78:2<311::AID-CNCR19>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

2.  Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases.

Authors:  Véronique Duhem-Tonnelle; Matthieu Vinchon; Anne-Sophie Defachelles; Anne Cotten; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2005-12-21       Impact factor: 1.475

Review 3.  A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Curr Pediatr Rev       Date:  2014

Review 4.  Neuroblastoma.

Authors:  S Shah; Y Ravindranath
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 1.967

5.  Intraspinal Extension of Neuroblastoma: a Report of Two Cases.

Authors:  Kartik Chandra Mandal; Pankaj Halder; Bidyut Debnath; Mala Bhattacharya
Journal:  Indian J Surg Oncol       Date:  2019-11-20

6.  Neonatal neuroblastoma.

Authors:  J Moppett; I Haddadin; A B Foot
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-09       Impact factor: 5.747

7.  Neurological complications of neuroblastic tumors: experience of a single center.

Authors:  G Burca Aydin; M Tezer Kutluk; Munevver Buyukpamukcu; Canan Akyuz; Bilgehan Yalcin; Ali Varan
Journal:  Childs Nerv Syst       Date:  2009-08-28       Impact factor: 1.475

Review 8.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Clinical characteristics and therapeutic outcomes of mediastinal neuroblastoma with intraspinal extension: a retrospective study.

Authors:  Jue Tang; Dan Zhang; Ying-Yi Xu; Xin-Ke Xu; Feng-Hua Wang; Jia-Hang Zeng; Jiang-Hua Liang; Wei Liu; Le Li
Journal:  Transl Pediatr       Date:  2021-04

10.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Authors:  H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.